The Military Chemical and Pharmaceutical Plant of the Agenzia Industrie Difesa (AID) has been officially registered in the National Research Registry maintained by the Italian Ministry of Universities and Research, thereby acquiring eligibility to access public funding in the fields of scientific research and training.

This recognition marks a significant step forward in the Agency’s strategic commitment to supporting research, technological innovation, and national health resilience. In this context, AID has already outlined a structured investment plan for the Florence Plant, home to the Centre for Pharmacology and Applied Chemistry, with the objective of strengthening research into rare diseases and highly complex pathological conditions, placing particular emphasis on biotechnological innovation and advanced medical technologies.

The primary mission is to provide both military and civilian communities with access to safe, effective, and high-quality pharmacological treatments, aligned with the most rigorous standards of excellence.

Thanks to its inclusion in the Registry, the Plant will be able to broaden its participation in national and international calls for research and training projects, particularly in areas related to public health, biomedical innovation, and individual well-being.

This development integrates and enhances the value of existing initiatives already underway, including:

• NUTESA – Development of a Sustainable Nutraceutical to Counter Overtraining Syndrome;
• FITNESS – Cannabis Phytocomplexes in Physical Activity and Post-Traumatic Stress Disorder;
• MANDRA – Active Molecules for Radiological and Nuclear Protection;
• DISA 2.0 – Review and Modernization of the Joint Anti-Poison Medical Equipment Kit.

In parallel, the Plant is actively evaluating new innovative projects focused on the identification of novel pharmacological classes and advanced pharmaceutical technologies.

Among the most promising collaborations is that with the FIRMO Foundation, which is paving the way for cutting-edge research into the biochemical mechanisms of cannabis, with potential therapeutic applications in bone disease treatment. A tangible result of this synergy is the Plant’s recent participation in the AIFA national research call dedicated to the fight against rare diseases.